Presenting the European forum for TB innovation: Innovative thinking in progressing towards TB elimination in Europe

European Respiratory Journal

Volumn 40, Issue 4, 2012, Pages 806-808

  Blasi, Francesco ^a   Reichman, Lee B ^c   Migliori, Giovanni Battista ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b IRCCS   (Italy)

^c RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOLOGIST; CLINICAL PRACTICE; DISEASE TRANSMISSION; EDITORIAL; ESTONIA; EUROPE; EXPERIMENTAL THERAPY; HEALTH CARE DELIVERY; HEALTH CARE POLICY; HEALTH PROGRAM; INFECTION CONTROL; MASS COMMUNICATION; MEDICAL SOCIETY; MULTIDRUG RESISTANT TUBERCULOSIS; PATIENT CARE; PNEUMONIA; PRIORITY JOURNAL; PROFESSIONAL STANDARD; RESPIRATORY CARE; SCIENTIFIC LITERATURE; TUBERCULOSIS; TUBERCULOSIS CONTROL; USSR; WORLD HEALTH ORGANIZATION;

DISEASE ERADICATION; EUROPE; HUMANS; TUBERCULOSIS;

EID: 84867115777     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00080212     Document Type: Editorial

References (15)

1. Zignol M, van Gemert W, Falzon D, et al. Surveillance of anti-tuberculosis drug resistance in the world: an updated analysis, 2007-2010. Bull World Health Organ 2012; 90: 111D-119D.
2. Skrahina A, Hurevich H, Zalutskaya A, et al. Alarming levels of drug-resistant tuberculosis in Belarus: results of a survey in Minsk. Eur Respir J 2012; 39: 1425-1431.
3. Leimane V, Dravniece G, Riekstina V, et al. Treatment outcome of multidrug/extensively drug-resistant tuberculosis in Latvia, 2000-2004. Eur Respir J 2010; 36: 584-593.
4. Floyd K, Hutubessy R, Kliiman K, et al. Cost and cost-effectiveness of multidrug-resistant tuberculosis treatment in Estonia and Russia. Eur Respir J 2012; 40: 133-142.
5. Migliori GB, Sotgiu G, Lange C, et al. Extensively drug-resistant tuberculosis: back to the future. Eur Respir J 2010; 36: 475-477.
6. Balabanova Y, Radiulyte B, Davidaviciene E, et al. Risk factors for drug-resistant tuberculosis patients in Lithuania, 2002-2008. Eur Respir J 2012; 39: 1266-12699.
7. Fattorini L, Migliori GB, Cassone A, et al. Proficiency testing of first- and second-line anti-tuberculosis drugs in Italy. Eur Respir J 2012; 39: 1263-1266.
8. Fattorini L, Mustazzolu A, Piccaro G, et al. Drug-resistant tuberculosis among foreign-born persons in Italy. Eur Respir J 2012; 40: 497-500.
9. Raviglione MC, Uplekar MW. WHO's new Stop TB Strategy. Lancet 2006; 367: 952-955.
10. Raviglione M, Marais B, Floyd K, et al. Scaling-up interventions to achieve global tuberculosis control: progress and new developments. Lancet 2012; 379: 1902-1913.
11. Fox W, Ellard GA, Mitchison DA. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications. Int J Tuberc Lung Dis 1999; 3: Suppl. 2, S231-S279. (Pubitemid 29481843)
12. Mitchison DA. The diagnosis and therapy of tuberculosis during the past 100 years. Am J RespirCrit Care Med 2005; 171: 699-706. (Pubitemid 40471139)
13. Migliori GB, Zellweger JP, Abubakar I, et al. European Union Standards for Tuberculosis Care. Eur Respir J 2012; 39: 807-819.
14. Broekmans JF, Migliori GB, Rieder HL, et al. European framework for tuberculosis control and elimination in countries with a low incidence. Recommendations of the World Health Organization (WHO), International Union Against Tuberculosis and Lung Disease (IUATLD) and Royal Netherlands Tuberculosis Association (KNCV) Working Group. Eur Respir J 2002; 19: 765-775.
15. Sterling TR, Villarino ME, Borisov AS, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med 2011; 365: 2155-2166.